Rohto Pharmaceutical Co Ltd
TSE:4527

Watchlist Manager
Rohto Pharmaceutical Co Ltd Logo
Rohto Pharmaceutical Co Ltd
TSE:4527
Watchlist
Price: 2 854.5 JPY -0.4%
Market Cap: 674.2B JPY
Have any thoughts about
Rohto Pharmaceutical Co Ltd?
Write Note

Rohto Pharmaceutical Co Ltd
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Rohto Pharmaceutical Co Ltd
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Rohto Pharmaceutical Co Ltd
TSE:4527
Current Portion of Long-Term Debt
ÂĄ24.3B
CAGR 3-Years
64%
CAGR 5-Years
70%
CAGR 10-Years
10%
Shiseido Co Ltd
TSE:4911
Current Portion of Long-Term Debt
ÂĄ144B
CAGR 3-Years
77%
CAGR 5-Years
33%
CAGR 10-Years
4%
Kao Corp
TSE:4452
Current Portion of Long-Term Debt
ÂĄ56.4B
CAGR 3-Years
37%
CAGR 5-Years
4%
CAGR 10-Years
11%
Kose Corp
TSE:4922
Current Portion of Long-Term Debt
ÂĄ1.5B
CAGR 3-Years
98%
CAGR 5-Years
46%
CAGR 10-Years
25%
F
Fancl Corp
TSE:4921
Current Portion of Long-Term Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Kobayashi Pharmaceutical Co Ltd
TSE:4967
Current Portion of Long-Term Debt
ÂĄ371m
CAGR 3-Years
30%
CAGR 5-Years
20%
CAGR 10-Years
13%
No Stocks Found

Rohto Pharmaceutical Co Ltd
Glance View

Market Cap
651.2B JPY
Industry
Consumer products

Rohto Pharmaceutical Co Ltd., a company deeply rooted in the legacy of Japanese innovation, traces its beginnings to the late 19th century. Initially specializing in over-the-counter (OTC) medicines, it has adeptly expanded its reach to include skincare and healthcare products. The company’s journey from its inception was marked by a relentless pursuit of addressing the evolving needs of its consumer base, leveraging its expertise in pharmaceuticals and chemistry to create products that cater to health and wellness. Rohto's commitment to research and development has enabled it to pioneer unique formulations, effectively blending traditional practices with modern scientific advances. This strategy has allowed Rohto to establish a strong foothold not only in Japan but also in international markets, appealing to a broad demographic. The core of Rohto's business lies in its ability to commercialize its innovative solutions across various channels. The company generates revenue primarily through the sale of its diversified product lines, which include eye drops, dermatological creams, and other personal care products. Rohto’s strategic acquisitions and partnerships have also played a critical role in its growth, enabling it to expand its market presence and adapt to global health trends. The ability to anticipate and respond to consumer needs allows Rohto to maintain a robust product pipeline, ensuring consistent sales performance. Through its global distribution networks and focused marketing efforts, Rohto capitalizes on its brand reputation for quality and reliability, ensuring a steady stream of profits.

Intrinsic Value
3 201.93 JPY
Undervaluation 11%
Intrinsic Value
Price

See Also

What is Rohto Pharmaceutical Co Ltd's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
24.3B JPY

Based on the financial report for Sep 30, 2024, Rohto Pharmaceutical Co Ltd's Current Portion of Long-Term Debt amounts to 24.3B JPY.

What is Rohto Pharmaceutical Co Ltd's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 10Y
10%

Over the last year, the Current Portion of Long-Term Debt growth was 483%. The average annual Current Portion of Long-Term Debt growth rates for Rohto Pharmaceutical Co Ltd have been 64% over the past three years , 70% over the past five years , and 10% over the past ten years .

Back to Top